Last reviewed · How we verify
E7820 plus cetuximab
E7820 plus cetuximab is a Combination therapy (integrin inhibitor plus EGFR inhibitor) Small molecule drug developed by Eisai Inc.. It is currently in Phase 2 development.
E7820 inhibits integrin α2 expression while cetuximab blocks EGFR signaling, providing dual anti-tumor activity.
E7820 is an inhibitor of the epidermal growth factor receptor, and it is being studied in combination with cetuximab, an antibody that also targets the epidermal growth factor receptor, for the treatment of advanced colorectal cancer.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | E7820 plus cetuximab |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | Combination therapy (integrin inhibitor plus EGFR inhibitor) |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
E7820 is a small molecule that suppresses integrin α2 subunit expression, which may inhibit tumor angiogenesis and metastasis. Cetuximab is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR), blocking downstream signaling pathways involved in tumor cell proliferation and survival.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E7820 plus cetuximab CI brief — competitive landscape report
- E7820 plus cetuximab updates RSS · CI watch RSS
- Eisai Inc. portfolio CI
Frequently asked questions about E7820 plus cetuximab
What is E7820 plus cetuximab?
How does E7820 plus cetuximab work?
Who makes E7820 plus cetuximab?
What drug class is E7820 plus cetuximab in?
What development phase is E7820 plus cetuximab in?
Related
- Drug class: All Combination therapy (integrin inhibitor plus EGFR inhibitor) drugs
- Manufacturer: Eisai Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing